Pharma company challenges cancer treatment award
A Taiwanese pharmaceuticals company has challenged an award issued in a €2 billion ICC dispute over a blood cancer drug, arguing it was not allowed to defend itself against a claim raised later in the proceedings.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.